Objective: To determine whether a significant number of patients with hyperparathyroidism remain undiagnosed and untreated. Background: Failure to diagnose primary hyperparathyroidism and refer patients to surgeons leads to impaired quality of life and increased costs. We hypothesized that many patients with hyperparathyroidism would be untreated due to not considering the diagnosis, inadequate evaluation of hypercalcemia, and under-referral to surgeons. Methods: We reviewed administrative data on 682,704 patients from a tertiary referral center between 2011 and 2015, and identified hypercalcemia (>10.5 mg/dL) in 10,432 patients. We evaluated whether hypercalcemic patients underwent measurement of parathyroid hormone (PTH), had documentation of hypercalcemia/hyperparathyroidism, or were referred to surgeons. Results: The mean age of our cohort was 54 years, with 61% females, and 56% whites. Only 3200 (31%) hypercalcemic patients had PTH levels measured, 2914 (28%) had a documented diagnosis of hypercalcemia, and 880 (8%) had a diagnosis of hyperparathyroidism in the medical record. Only 592 (22%) out of 2666 patients with classic hyperparathyroidism (abnormal calcium and PTH) were referred to surgeons. Conclusions: A significant proportion of patients with hyperparathyroidism do not undergo appropriate evaluation and surgical referral. System-level interventions which prompt further evaluation of hypercalcemia and raise physician awareness about hyperparathyroidism could improve outcomes and produce long-term cost savings.
F
ailure to diagnose and treat hyperparathyroidism leads to impaired quality of life and increases costs for patients and health systems. [1] [2] [3] [4] [5] [6] Untreated hyperparathyroidism increases the risk of fractures and kidney stones, is associated with depression and cognitive impairment, and can cause cardiovascular dysfunction that leads to hypertension, stroke, and myocardial infarction. 6 The only effective treatment for hyperparathyroidism is parathyroidectomy, which can be performed in an outpatient setting with minimal morbidity and offers a durable cure for 85% to 95% of patients. 6, 7 Multiple opportunities exist for health care systems to underdiagnose or undertreat hyperparathyroidism. Although surgeons provide the definitive treatment for hyperparathyroidism, the diagnosis is typically made by primary care physicians who then refer to endocrinologists and/or surgeons for further assessment and discussion about treatment. Diagnosing hyperparathyroidism requires a high index of suspicion because symptoms are often nonspecific, and the first indication of disease is usually an elevated calcium on routine laboratory tests. 8 Prior work suggests that hyperparathyroidism may be underdiagnosed and undertreated, but these studies used parathyroidectomy as the primary endpoint. They did not distinguish between patients who were untreated due to nonreferral to surgeons and those who underwent surgical evaluation but opted not to have surgery. [9] [10] [11] Not all patients with hyperparathyroidism will decide to have surgery, and surgeons will typically not recommend a procedure when the patient's health status suggests that risks outweigh benefits. If the purpose of health care systems is to take a patient-centered approach to care, then care processes should ideally help patients reach the physician who can help them make informed treatment decisions. When it comes to decisions about parathyroid surgery, surgeons represent the best source of information on risks and benefits. Consequently, we felt that referral to surgeons represents a more useful endpoint than whether patients ultimately undergo parathyroidectomy.
The purpose of this study is to (1) evaluate whether patients with hypercalcemia receive the appropriate biochemical evaluation with assessment of parathyroid hormone (PTH) levels, and (2) determine rates of surgical referral and treatment for hyperparathyroidism. We hypothesized that a significant number of patients with hypercalcemia would not have their PTH levels evaluated, and that there would be opportunities to improve rates of referral to surgeons for patients with hyperparathyroidism.
METHODS

Patient Population
Setting
We used administrative data to review 682,704 consecutive patients seen at the University of Alabama at Birmingham (UAB), a tertiary referral center, from 2011 to 2015 (Fig. 1 ).
Referral to Surgeons and Endocrinologists
To ascertain whether patients were referred to surgeons or endocrinologists for evaluation of hyperparathyroidism, we performed a free text search of all notes in the medical record system. We searched for signatures that contained the names of surgeons and endocrinologists employed at UAB during the study period. If patients had a note signed by either a surgeon who performs parathyroidectomies or an endocrinologist, they were considered to have been seen by that physician and were categorized as having been referred to surgery or endocrinology.
Patient Characteristics
Demographic information such as age, sex, and insurance status was obtained from the electronic medical record. Comorbidities were classified using the Elixhauser method based on ICD-9 or ICD-10 codes in medical records. 12 Elixhauser comorbidities include HIV/AIDS, alcohol abuse, arrhythmia, pulmonary disease, hypertension, heart failure, anemia, diabetes, drug abuse, fluid/electrolyte disorders, hypothyroidism, liver disease, lymphoma, malnutrition/ weight loss, cancer, obesity, neurologic disorders, paralysis, ulcers, peripheral vascular disease, psychoses, renal failure, and cardiac valve disorders. A similar process was used to assess whether patients had complications of hyperparathyroidism, including kidney stones, osteoporosis/osteopenia, and fractures.
Statistical Analysis
We used 2-tailed t tests to compare means, chi-square for univariable comparisons of proportions, and multivariable logistic regression to identify independent predictors of (1) checking PTH levels, and (2) odds of referral to surgeons or endocrinologists. An alpha of <0.05 was considered statistically significant. Analyses were performed using SAS.
RESULTS
Patient Characteristics
We reviewed administrative data on 682,704 consecutive patients from a tertiary referral center between 2011 and 2015, and 315,300 patients had their serum calcium evaluated (Fig. 1) . FIGURE 1. Most patients with hypercalcemia do not receive appropriate evaluation of PTH levels or referral to surgeons for discussion of treatment options.
Characteristics of Patients Who Received Appropriate Biochemical Evaluation of Hypercalcemia
Only 3200 (31%) patients with hypercalcemia received an appropriate biochemical workup with evaluation of PTH levels, whereas 7232 (69%) patients never had their PTH levels checked. Patients who had PTH checked were more likely to be older (mean age 60.7 vs 51.3 years) and female (68% vs 59%) compared with those who did not have PTH evaluated (Table 2) . Patients who had PTH evaluated were also more likely to be seen in an outpatient setting, and they were less likely to have Elixhauser comorbidities (Table 2) . Multivariable logistic regression indicated that predictors of appropriate workup for hypercalcemia included age (youngest and oldest patients less likely), female sex, commercial/private insurance, higher calcium levels, the absence of Elixhauser comorbidities, and the presence of osteoporosis or kidney stones (Fig. 2) .
Characteristics of Patients With Abnormal Calcium and PTH Who Were Referred for Surgical Evaluation
Among the 3200 patients who had both calcium and PTH evaluated, the chances of surgical referrals decreased for older patients (>75 years old), men, and individuals with Elixhauser comorbidities (Table 3 ). In addition, the rates of diagnosis (hyperparathyroidism or hypercalcemia) and referral to surgeons varied according to the PTH levels ( Fig. 1) . Patients with PTH levels above the normal values for the assay (>85 pg/mL) were correctly diagnosed with either hypercalcemia or hyperparathyroidism 76% of the time, but only 462 (29%) patients were referred to surgeons (Fig. 1 ). In addition, among patients with inappropriately high PTH given their calcium levels (normohormonal hyperparathyroidism), 21% with PTH 66 to 85 pg/mL and 8% with PTH 21 to 65 pg/mL were referred to surgeons. We repeated this analysis for patients who had !2 abnormal calcium values and found similar rates of surgical referrals (data not shown). Similarly, hypercalcemia or hyperparathyroidism was correctly diagnosed for 22 patients (70%) in the PTH 66-85 group and 541 (72%) patients in the PTH 21 to 65 group. Less than 4% of patients with elevated calcium and PTH <21 pg/mL were referred to surgery, though 234 (69%) patients were diagnosed with either hypercalcemia or hyperparathyroidism. After adjusting for differences in patient characteristics, both old [odds ratio (OR) 0.27 for age >85 years) and young age (OR 0.42 for age <35 years) and male sex (OR 0.78) were associated with lower odds of surgical referral (Fig. 3) . Patients without any Elixhauser comorbidities (OR 2.3) and higher calcium levels (OR 1.14-1.85 for calcium >11.1 mg/dL) were more likely to be referred to surgeons. A similar analysis to assess rates of referral to medical endocrinologists (Table 4 and Fig. 4 ) identified only 385 out of 3,200 (12%) patients who were referred to endocrinologists after both calcium and PTH were evaluated. The only factor in our model that predicted the likelihood of an endocrine referral was male sex (OR 0.64). Age, race/ethnicity, insurance status, and serum calcium were not significant predictors.
DISCUSSION
Our primary finding was that very few patients with hypercalcemia undergo evaluation of PTH levels to identify the underlying etiology, and an even smaller minority with both abnormal calcium and PTH are referred to surgeons to discuss treatment. Although not all patients with hyperparathyroidism need or desire surgery, the most appropriate health care provider to discuss risks and benefits of parathyroidectomy is a surgeon. Unfortunately, we found that 71% of patients with clear hyperparathyroidism (abnormal calcium and PTH) never see a surgeon to discuss treatment options. In addition, >80% of patients with inappropriately high PTH in the setting of hypercalcemia, who might also benefit from surgery, never receive a surgical referral. Parathyroidectomy is a low-risk procedure that can improve quality of life, enhance bone health, and reduce risk of kidney stones. Our analysis identified considerable opportunity for health systems to improve the diagnosis and treatment of hyperparathyroidism, given how many patients miss the opportunity to even discuss the benefits of surgery.
Our findings expand upon earlier work that explored diagnosis and treatment of hyperparathyroidism. Yeh et al used administrative data from Kaiser Permanente in California to determine whether patients with primary hyperparathyroidism were undergoing parathyroidectomy when they met consensus recommendations for surgery. In this group of patients who would be expected to have high rates of surgery, only 39%-51% actually had parathyroidectomy. 9 They looked at individual criteria for surgery and found that patients with nephrolithiasis were more likely to undergo surgery, but that significant bone density changes did not increase the odds of surgery. The study indicated that rates of parathyroidectomy remained low even when patients clearly met indications for surgery, but the authors were unable to determine whether patients discussed parathyroidectomy with a surgeon and opted not to have the operation, or FIGURE 2. Odds of PTH levels evaluated after hypercalcemia vary with age, sex, insurance status, comorbidity, and calcium level. Odds ratios and 95% confidence intervals shown on the left, with numeric value of odds ratio shown on the right. Results adjusted for type of visit (inpatient, outpatient, emergency room), year of initial calcium, and Elixhauser comorbidities.
FIGURE 3.
Odds of being referred to surgery after hypercalcemia and evaluation of PTH vary with age, sex, comorbidity, and calcium level. Odds ratios and 95% confidence intervals shown on the left, with numeric value of odds ratio shown on the right. Results adjusted for type of visit (inpatient, outpatient, emergency room), year of initial calcium, and Elixhauser comorbidities.
were deemed too high risk by their surgeon. Press et al reviewed medical records at the Cleveland clinic for patients with elevated calcium and estimated that 43% of hypercalcemic patients were likely to have hyperparathyroidism and should undergo further evaluation and referral to endocrine surgeons. 10 Their study illustrates the importance of following up an abnormal calcium with a detailed history and measurement of PTH levels. The commentary on this article astutely noted that despite mounting evidence on the benefits of parathyroidectomy, little practice change has occurred at the level of primary care physicians to improve detection and increase surgical referrals. 13 Many potential explanations exist for low rates of diagnosis and treatment of hyperparathyroidism that could be addressed by clinical interventions. Primary care physicians are increasingly overwhelmed by a growing number of laboratory alerts, clinical messages, and paperwork.
14 It would be relatively easy to miss or ignore an isolated abnormal laboratory value, such as a high calcium, that arises during an otherwise routine assessment. Alternatively, the abnormal calcium might be noted but deemed low priority as it is rarely immediately life-threatening. Patients also may see different physicians at subsequent office visits, particularly at an academic center with resident involvement. In the current busy clinical environment, there may be insufficient time to review all previous laboratory values and the need to follow up on a previously high calcium may be missed.
There are also several reasons why patients with hyperparathyroidism may not be referred for surgical evaluation. Primary care physicians may assume that surgeons have no role to play unless patients meet some of the consensus criteria for surgery, including a history of kidney stones, bone changes, elevated creatinine, and so on. 6 Although these guidelines are meant to help with the decision to operate, it seems reasonable that patients would benefit from evaluation by an expert who could discuss the risks and benefits of surgery and fully engage with patients in making treatment decisions. Indeed, the recent American Association of Endocrine Surgery guidelines emphasize the importance of referring patients to surgical experts for discussion of treatment options. 6 In addition, busy primary care physicians may be falsely reassured when they check PTH levels and the results fall within the ''normal'' range for the assay. Classic hyperparathyroidism consists of elevated calcium and PTH, but normohormonal hyperparathyroidism is also a recognized entity where PTH is inappropriately high in the setting of elevated calcium, It is also important to acknowledge that patients may not be interested in surgery when they have reasonable quality of life and are not experiencing significant symptoms. At the same time, surgeons may not recommend an operation for patients who are high risk and likely to derive little benefit from parathyroidectomy. We consider it important to emphasize that regardless of patient comorbidity or symptoms, a surgeon is still the optimal person to have an informed discussion about risks and benefits of parathyroidectomy. Surgeons are more likely than medical specialists to understand the risks of surgery and to effectively determine how their skill level and patients' health status intersect to determine operative risk. Surgeons are also well equipped to address questions about operative technique and postoperative recovery that are important for patients to make informed decisions. In short, patients with hyperparathyroidism are likely to gain valuable information and insight from talking to surgeons even if they ultimately decide not to have surgery. If nothing else, it will ensure that patients are aware of treatment options, and they may reconsider the value of surgery at a later date, or if their disease progresses.
Our study provides a detailed picture of deficiencies in the clinical approach to hypercalcemia and hyperparathyroidism, but several limitations should be acknowledged. The number of patients is substantial, but they are all derived from a single institution's health system. UAB draws patients from a wide geographic area and maintains excellent follow-up, but it is entirely possible that some individuals received evaluation and treatment at other institutions and this was not captured by our analysis. Our mean follow-up was 16 months, however, which suggests that most patients were seen in the UAB system long enough to undergo appropriate evaluation and referral. We also found that patients with !2 abnormal calcium values had similarly low rates of surgical referral, which suggests that loss to follow-up is unlikely to explain our findings. In addition, the approach to hyperparathyroidism and hypercalcemia at UAB may not be representative of practice patterns nationally. We feel that this is unlikely, however, given similar results found in other health systems.
9,10 Finally, any retrospective study involving administrative data is subject to error related to coding of comorbidity and other demographic data.
In summary, we found strong evidence for a need to change how health systems approach diagnosis and treatment of hypercalcemia and hyperparathyroidism. There is a significant opportunity to improve patient outcomes by earlier detection and treatment of a problem that can impact multiple organ systems and greatly impair quality of life. Although this study did not examine the impact of underdiagnosis and undertreatment on health outcomes (mortality, clinic visits, hospitalization, use of medications, and costs of care), it would be reasonable to expect that delays in diagnosis could affect these outcomes. Future work can further elaborate the health implications of failure to diagnose and treat hyperparathyroidism in a timely fashion. Changing the approach to hypercalcemia and hyperparathyroidism will require interventions that affect multiple levels of care. Engaging with primary care providers to increase awareness of hyperparathyroidism and the benefits of modern surgical approaches to the disease are important. At the same time, it will be necessary to engage with patients to ensure they are active participants in the process and are able to advocate for effective diagnosis and treatment. Finally, automated processes that ensure appropriate laboratory evaluations and referrals can reduce error by minimizing the risk of missed laboratory values or misdiagnosis of hyperparathyroidism. The combination of systems changes and stakeholder engagement is more likely to succeed than focusing on one component to the exclusion of others. 16 This will better enable hospitals and providers to care for patients with a frequently overlooked diagnosis. 
DISCUSSANTS Dr John A. Olson (Baltimore, MD):
We have just heard another important contribution to the endocrine surgical literature from Dr Chen's research group, now at the University of Alabama. Dr Balentine, that was an outstanding presentation, and you have taken great care to take advantage of a large repository of clinical data from the UAB electronic medical record to ascertain patterns of care for patients who had serum calcium determination and hypercalcemia identified. You have demonstrated that a significant percentage of the population of patients at your institution have, in fact, hypercalcemia. However, only about a third of these patients receive an appropriate diagnostic workup and fewer than a quarter are referred for surgical treatment. This is unfortunately a previously told story, and the results of your study confirm a disturbing trend that only a minority of patients are referred for appropriate surgical therapy. Despite the fact that parathyroidectomy for hyperparathyroidism is curative in >90% of patients, and that parathyroidectomy has a low risk of complications, many primary care providers and endocrinologists either do not notice hypercalcemia or dismiss it as unimportant to the overall health of their patients. This is unfortunate given a wealth of clinical information clearly showing that hyperparathyroidism leads to significant morbidity.
The appropriate question is, who accrues what benefits from curing hypercalcemia, and how much benefit is to be expected in the context of other comorbidities? We have all seen patients who feel remarkably better and have improvement in their quality of life after successful parathyroidectomy, and it makes us wonder how many patients at UAB and beyond could be leading better lives if they were appropriately diagnosed and treated?
I have 3 questions for you: 2 are specific to your data and 1 addresses your proposal for next steps. The criterion for your study inclusion was a single elevated calcium level, which may overinflate the magnitude of the problem. Of the 10,432 identified patients, how many of these patients had at least 2 abnormal calcium levels and therefore should have been more appropriately evaluated for further etiology and specialist referral?
My second question is that you spoke of the absence of comorbidities as positively predictive of both workup and referral.
That means many patients with significant comorbidities either were not appropriately worked up or were not referred for therapy, and this may be understandable. Can you elaborate on which comorbidities were of greatest influence to these outcomes, and were you able to discern whether the absence or presence of known sequela of hyperparathyroidism such as kidney stones, fracture, or neurocognitive impairment were associated with referral for treatment?
Lastly, quality improvements are often easy to identify, but it is often hard to effect change. You have given some nice steps for how to automate the process of diagnosis and referral and perhaps take the doctor out of the equation. I would submit to you that this is unlikely to be an effective strategy. Instead, perhaps this type of paper could be presented to the audience that would benefit most, the primary care physicians and endocrinologists.
Dr Balentine, I congratulate you and your coauthors on a wellperformed and nicely presented study.
This article is a significant contribution to the literature on parathyroid disease and is a very nice example of the power of institutional clinical data repositories to identify areas for process and quality improvement in health care systems. Thank you very much.
Response from Dr Courtney Balentine (Birmingham, AL):
Thank you for the kind words and the great questions. I'll try to answer them in order.
Your first question is a great question about the design of how we put this together. It is something that we struggled with thinking about how is the best way to do it since most of the literature out there has, in fact, used 2 abnormal calcium as the cut point for entering into a cohort of this type. We deliberately chose not to do that.
I think it was a bit of a philosophical and bit of a design decision in the sense that we are trying to make an argument that there are a lot of patients out there who start out with a single high calcium and then either somebody repeats it and it comes back high normal or slightly abnormal and kind of gets written off. So to make the argument that the appropriate workup is not happening, we decided to focus on patients that had that single initial calcium, making the point that the next step is not repeating the calcium. It is repeating the calcium and the PTH. We are checking the PTH within close proximity to really make the diagnosis.
We did not specifically look at the number of abnormal calcium, so I cannot directly answer your question. What I can tell you is that part of our next step is a mixed-methods study to figure out what is really going on here. We started out on the chart review portion of that. I can tell you anecdotally from the subset reviewed in the chart, probably about 80%-90% of the patients have multiple abnormal calcium before any further workup or further treatment is actually initiated. I suspect it is a pretty high number and would not change a lot of the conclusions, but that is kind of our thinking behind that particular design decision.
In terms of the comorbidities and the sequelae, the data ended up being a lot messier than I thought it would be, honestly. Some of the comorbidities that came up as predictors, for example, diabetes and hypertension actually were significant predictors of less likelihood for both diagnosis and referral as were different types of cancer. I was not totally sure what to make of that and we are still thinking about it.
In terms of the sequelae specifically of hyperparathyroidism, again, we put in code for things like kidney stones and fractures and that sort of thing, thinking that would help drive at least the rate of referral, if not the rate of diagnosis. And what I found actually is that there is a pretty good discrepancy between what gets diagnosed in the system and what is actually in the chart. In looking in the chart, there are a lot of patients that have those comorbidities that are not getting coded. So at the moment, I do not have a great answer for that. I am hoping that the next study will give us a better sense how those different factors actually drive decisions along the process.
Finally, to your last question about actually operationalizing the intervention, you are absolutely right. In fact, I was naively coming into this thinking if we can build in a great system to help primary care doctors diagnose without having to think about it, they will love it. It will increase their referral rate. Wouldn't that be great?
We sat down with our endocrinology folks to kind of talk about their sense of the data and figure out mechanisms to work on going forward, and the first thing they said was, ''Yeah, we tried that; they hated it.'' So now we are thinking about next steps to take, to meet with the primary care doctors, and to get a better sense of how they think the system works and areas of improvement before we figure out what the next design is. We thought about a few things, including using machine learning algorithms, which is the focus of one of the research programs for one of our collaborators, to identify the patients that are really high risk and focusing on those for the intervention at first with the idea being if we target people that are really having the disease initially, then whatever intervention we come up with has a high rate of success at first, that will generate enough buy-in to make it more expansive and help out more patients.
Dr Nancy Perrier (Houston, TX):
Congratulations to you Courtney and to Dr Chen-on pulling together this very nice data. Your clustering of patients is valuable to assess downstream disability, which is the preventative sequelae of primary hyperparathyroidism. Cure is important for the present, but more importantly to prevent the downstream disability. What you have demonstrated is similar with what the Scandinavian cohort revealed about cardiovascular disease and death.
I wonder if this data set can use death as an outcome marker and calculate observed over expected mortality. The comparison of outcome of those you treated versus not treated would be the important objectively. This will also prompt inquiry of case mix index and outcomes. We wholeheartedly encourage you to bring these answers back to the Southern Surgical Association in years to come.
Response from Dr Courtney Balentine (Birmingham, AL):
That is absolutely a great point. We are thinking along those lines, not only death, but looking at clinic visits, ER visits. What are the actual medical costs of missing the diagnosis of hyperparathyroidism? Not only that, but how many times does the patient have to visit the doctor before somebody says, I do not understand why this patient has been with high calcium for 10 years. Maybe we should work it up.
So that is a great point, and we definitely are looking forward to doing that analysis.
Dr David J. Winchester (Evanston, IL):
My compliments to the authors for a well-presented article and a great study. We did a similar project at our hospital, looking at more stringent criteria with serum calcium levels above 11 along with elevated parathormone levels. Over a 10-year period, we identified about 700 patients of which only 51% were referred to surgeons using these criteria.
We did not see any association with sex or race/ethnicity. We did see correlation with age with older patients being less likely to be referred with comorbid conditions. So, clearly, this is an opportunity to educate referring physicians. We did not see any difference in referrals between primary care physicians and endocrinologists. Did you look for any difference between types of referring doctors? And finally, have you considered a best practice alert using your EMR to alert physicians? Thank you.
Response from Dr Courtney Balentine (Birmingham, AL):
One thing we did look at that I did not present today because of time is the actual rates of referrals to endocrinologists. That was not my idea, actually. That came from our conversation with the endocrinologists. The first question they asked was, I wonder how many of these patients are actually seeing us? The answer is an even smaller fraction than the number seeing surgeons. So about half of the rate of referral to surgeon, that is approximately the rate of referral to endocrinologists. In fact, it was so low that I went back to them and asked, does this even seem right? Are we missing something? Is our algorithm incorrect? Is there any way this is possibly right? And their answer was, yeah, probably it is.
So I think there is a big disconnect between referrals to surgeons and referrals to endocrinologists from the primary care level. Whether that is an issue of the primary care clinics feel like they are doing a good job and do not need to refer, or only the trickiest cases get referred to an endocrinologist. I am not sure. We did not specifically look at the rates of referral from endocrinologists as opposed to other physicians. I think that is an interesting point and worth exploring.
In terms of building in the alerts into the system, we are talking to the IT about doing that now, and they feel like it is something they can build in. Meaning it can pop up. In a patient who has high calcium, we are building in an automatic order to whatever physician; this will be followed up by so on. We talked to the endocrinologists about designating some of them as sort of pan university PTH receivers. Meaning, anybody that gets that lab order, the endocrinologist would follow up on it. They clearly love the idea of getting more referrals. But, again, they pointed out to us they tried something similar with the primary care system in the past and it had not gone well. So we are still in the very, very early stages of trying to feel out the primary care division and getting a sense of, is that something acceptable to them now given the data that we have got? Do we need to get a little further along the line first? It is kind of a delicate phase of that process, but we are thinking along those lines for sure.
Dr Samuel Snyder (Harlingen, TX):
I applaud you for undertaking this study, and I agree wholeheartedly with your results. I am dismayed often when I see patients that have this disease and get repeatedly diagnosed before they get referred to a surgeon that can fix it. I am interested because your abstract mentions cost savings. The internist may argue, well, if I do not refer the patient to the surgeon and the patient never gets an operation, I am actually saving money. Were you able to put some quantity to your statement that it saves cost? My second question refers to patients that get the diagnosis of hyperparathyroidism, but yet do not get a referral to a surgeon. I was a little dismayed by that. In my practice, what I see is the patient gets diagnosed with hyperparathyroidism over and over and over again, or there is a length of time before we finally get a chance to see that patient. Did you look at how many patients with the diagnosis then get rediagnosed and rediagnosed without a referral?
That is a great question. I think the cost-saving question really comes back to what Dr Perrier was talking about; we still have to analyze the number of clinic visits, referrals, new prescriptions, mortality, and other things that can drive costs. We do not have a hard number to put on there. That is sort of in our next phase of analysis. And I hope it will be as interesting to us as it is to everyone else. So I think there is going to be some pretty big cost savings when you really think about how many trips the patient has to make before they actually get treated and what that is really saving.
For your second question, I do not have a great answer for it yet other than to, again, refer to anecdotes. As I mentioned, we are starting a mixed-methods study to try to figure out what the underlying mechanism is, and part of that is reading through charts, doing a kind of narrative analysis of the patient's adventure from calcium being high to actually being treated. And we have done about 50 charts so far and I have been a little bit flabbergasted by how many excuses there are for either not checking a PTH or not referring once the diagnosis is there. Not excuses in a bad sense, but how many reasons people run through of this patient probably would not benefit from the surgery; the risk is too high; he or she does not want X, Y, or Z to happen. I think if they just refer to the surgeon to have the conversation, we might very well agree with them, but at least we can have the conversation with the patient, and I think it would make more sense for them long term with that approach.
Dr Peter Angelos (Chicago, IL):
Courtney, great study. Thank you for presenting. I have a question about the methodology and how much we can interpret from this. Things may be very different in Birmingham.
In Chicago, I see lots of patients who may have gotten a lab study at the University of Chicago with their orthopedic surgeon, but they have an internist at Rush and an endocrinologist out in the community.
So there is no sense in which the fact that they did not have a calcium and a PTH level check together at the University of Chicago in no way reflects whether they had it assessed anywhere else in the world. So I do not know how you were able to control for that consideration and whether you think that that in any way diminishes the strength of your findings.
I think that is a great question and a very legitimate limitation of any single institution or even single region database that does not track people longitudinally outside the system. You are absolutely right. We cannot guarantee that a patient who had, say, a calcium of 12 at UAB did not go back home or visit their relative, get the doctor visit, and have the PTH checked. That is certainly a possibility.
One of the things we did do, and I did not get into the data much here, was look at the difference between inpatient, outpatient, and ER rates for when the first calcium was checked. More than 80% of the patients were coming from the outpatient setting and the primary care setting. So I think it is reasonable to assume at least most of those patients are getting serially followed in the system, although certainly not all of them.
The inpatient and ER are certainly a higher risk group for loss to follow-up. One of the analyses we are doing kind of going forward looking separately is actually time to event rather than a binary outcome. I think that will help us tease it out. What I can say is from year to year, at least, there was a little bit of variation in the rates of referral and treatment, but not a massive one.
So thinking about patient inflow and outflow out of our system, it seemed to be a pretty consistent feature of our system as a whole which indirectly argues against loss to follow-up, although certainly not totally convincing. I think you are absolutely right, it is definitely a limitation to consider.
